Grantham, Mayo, Van Otterloo & Co (GMO)
BIIB icon

Grantham, Mayo, Van Otterloo & Co (GMO)’s Biogen BIIB Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-80,000
Closed -$25.1M – 582
2017
Q3 		$25.1M Hold
80,000
– – 0.15% 105
2017
Q2 		$21.7M Buy
+80,000
New +$21.2M 0.12% 122

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s BIIB Position: Q4 2023 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of Biogen (BIIB) in Q4 2023, closing a stake of 56,740 shares — an estimated $14.6M sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in BIIB in Q2 2013 and held it in 39 quarters. The position peaked at $283M in Q1 2015. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q4 2023.

  • Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining Biogen position as of Q4 2023 after selling out during the quarter.
  • Grantham, Mayo, Van Otterloo & Co (GMO) sold 56,740 Biogen shares in Q4 2023, an estimated $14.6M.
  • Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Biogen in Q2 2013 and held it in 39 quarters.
  • Grantham, Mayo, Van Otterloo & Co (GMO)'s Biogen position peaked at $283M in Q1 2015.
  • 1,002 funds tracked by Wall St. Rank held Biogen as of Q4 2023.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q4 2023, filed 13 Feb 2024.